Showing results (161-170 of 232) with videos related to
Sort By:
Pageof 24
British Journal of Pharmacology|October 20, 2023
Formation and clearance of TNF-TNF inhibitor complexes during TNF inhibitor treatmentLea Catharina Berkhout, Merel Jeanne I'Ami, Simone Kruithof, et al.The Lancet. Gastroenterology & Hepatology|February 5, 2022
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trialSilvio Danese, Severine Vermeire, Geert D'Haens, et al.Journal of Crohn'S & Colitis|June 22, 2024
Recommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical TrialsCorey A Siegel, Victoria Rai, An Outtier, et al.Journal of Crohn'S & Colitis|December 3, 2010
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspectsMatthieu Allez, Konstantinos Karmiris, Edouard Louis, et al.The American Journal of Gastroenterology|January 8, 2025
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical TrialBruce E Sands, David T Rubin, Edward V Loftus, et al.Gastroenterology|July 15, 2015
Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel diseasePaolo Biancheri, Randall J Brezski, Antonio Di Sabatino, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 2, 2019
Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's DiseaseChristopher Ma, Krisztina B Gecse, Marjolijn Duijvestein, et al.Eclinicalmedicine|March 19, 2026
Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trialSeverine Vermeire, Jessica R Allegretti, Hyo Jong Kim, et al.Journal of Crohn'S & Colitis|September 30, 2016
Long-term Efficacy of Vedolizumab for Crohn's DiseaseSeverine Vermeire, Edward V Loftus, Jean-Frédéric Colombel, et al.Nature Communications|April 28, 2022
A systems genomics approach to uncover patient-specific pathogenic pathways and proteins in ulcerative colitisJohanne Brooks-Warburton, Dezso Modos, Padhmanand Sudhakar, et al.Pageof 24